Using TPS to Diagnose Childhood Tumors
Author Information
Author(s): W Rebhandl, B Rami, J Turnbull, FX Felberbauer, K Paya, D Bancher-Todesca, R Gherardini, M Mittlboeck, E Horcher
Primary Institution: University of Vienna Medical School
Hypothesis
Can tissue polypeptide-specific antigen (TPS) effectively differentiate between neuroblastoma, Wilms' tumor, and benign tumors in children?
Conclusion
Serum TPS levels are significantly elevated in children with neuroblastomas and Wilms' tumors, aiding in diagnosis and therapy monitoring.
Supporting Evidence
- TPS levels were significantly elevated in neuroblastoma and Wilms' tumors compared to healthy children.
- Successful treatment resulted in a decrease in TPS serum values.
- ROC analysis showed high sensitivity and specificity for both malignancies.
Takeaway
Doctors can use a blood test to check for a special marker that helps tell if kids have certain types of tumors.
Methodology
Serum TPS levels were measured using an ELISA kit in children with neuroblastomas, Wilms' tumors, and benign tumors.
Limitations
The number of cases assessed is small, limiting the ability to correlate TPS values with prognostic factors.
Participant Demographics
23 children with neuroblastomas (10 boys, 13 girls; mean age 2.2 years), 9 with Wilms' tumors (4 boys, 5 girls; mean age 3.7 years), and 22 with benign tumors (11 boys, 11 girls; mean age 2.3 years).
Statistical Information
P-Value
0.0172
Confidence Interval
129-339 for neuroblastoma, 128-429 for Wilms' tumor
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website